Deal Maker Link Resigns From Corange

Max Link's resignation as the CEO of Corange Ltd. will not affect the biotech deals he negotiated for Corange - the $206 million Protein Design Labs deal and the $220 million CellPro Inc. deal, according to Patrick Enright, senior vice president of finance and business development of Corange's Boehringer-Mannheim Therapeutics. However, the executive's exodus may influence any future blockbuster biotech investments by Corange, Enright said.

"Our ability to do biotech deals will change," said Enright, who was involved in both the CPRO and PDLI deals. "Although our interest has not diminished in biotech, with Link's departure the rules have changed, especially with getting deals approved," Enright said...